Omburtamab Emerging Drug Insight and Market Forecast - 2032

“Omburtamab Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about Omburtamab for Leptomeningeal Metastases in the 7MM. A detailed picture of the Omburtamab for Leptomeningeal Metastases in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the Omburtamab for Leptomeningeal Metastases. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the Omburtamab market forecast, analysis for Leptomeningeal Metastases in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Leptomeningeal Metastases.

Drug Summary

Omburtamab is a radiolabeled murine monoclonal antibody 8H9 (131I-8H9) under development to target the B7-H3-expressing cells in solid human tumors, carcinomas, sarcomas, and brain tumors. Several in-vitro/ex-vivo modeling has shown Omburtamab binds to an FG loop-dependent conformation on the B7-H3 molecule, a domain critical for its biological functions. It is a radio-immuno conjugate consisting of the iodine 131-radiolabeled murine IgG1 monoclonal antibody 8H9 directed against the surface immune-modulatory glycoprotein 4Ig-B7-H3 with potential radio-imaging and radio-immunotherapeutic use. Iodine I 131 monoclonal antibody 8H9 binds to 4Ig-B7-H3 (human B7-H3 with 4 Ig-like domains) and may be used to radio-image and/or destroy tumor cells that express tenascin. Omburtamab is a promising investigational agent for radioimmunotherapy of leptomeningeal metastases, Diffuse Intrinsic Pontine Glioma (DIPG), and malignant ascites.

Y-mAbs therapeutics is currently conducting a Phase II/III (NCT03275402) study of 131I-omburtamab radioimmunotherapy in patients with LM. The company is also conducting a Phase I/II (NCT04315246) study of 177Lu-DTPA-omburtamab and one Phase I (NCT00089245) study of 131I-omburtamab for testing its safety and efficacy in LM. 

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the Omburtamab description, mechanism of action, dosage and administration, research and development activities in Leptomeningeal Metastases.
• Elaborated details on Omburtamab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the Omburtamab research and development activity in Leptomeningeal Metastases details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around Omburtamab.
• The report contains forecasted sales of Omburtamab for Leptomeningeal Metastases till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Leptomeningeal Metastases.
• The report also features the SWOT analysis with analyst views for Omburtamab in Leptomeningeal Metastases.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Omburtamab Analytical Perspective

In-depth Omburtamab Market Assessment

This report provides a detailed market assessment of Omburtamab in Leptomeningeal Metastases in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Omburtamab Clinical Assessment

The report provides the clinical trials information of Omburtamab for Leptomeningeal Metastases covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Leptomeningeal Metastases is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Omburtamab dominance.
• Other emerging products for Leptomeningeal Metastases are expected to give tough market competition to Omburtamab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Omburtamab in Leptomeningeal Metastases.
• This in-depth analysis of the forecasted sales data of Omburtamab from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Omburtamab in Leptomeningeal Metastases.

Key Questions

• What is the product type, route of administration and mechanism of action of Omburtamab?
• What is the clinical trial status of the study related to Omburtamab in Leptomeningeal Metastases and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Omburtamab development?
• What are the key designations that have been granted to Omburtamab for Leptomeningeal Metastases?
• What is the forecasted market scenario of Omburtamab for Leptomeningeal Metastases?
• What are the forecasted sales of Omburtamab in the 7MM, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Leptomeningeal Metastases and how are they giving competition to Omburtamab for Leptomeningeal Metastases?
• Which are the late-stage emerging therapies under development for the treatment of Leptomeningeal Metastases?

This product will be delivered within 2 business days.